Multiple Myeloma: What Do We Do About Immunodeficiency?

Area of Science:

• Hematology
• Immunology
• Oncology

Background:

• Multiple myeloma (MM) is an incurable blood cancer causing immunodeficiency.
• This deficiency impairs the body's ability to fight cancer cells and infections.
• Current treatments substitute for immunity using immunotherapies and anti-infectious agents.

Purpose of the Study:

• To review current and emerging immunotherapies for multiple myeloma.
• To highlight the role of antibiotics in managing infections and their potential anti-tumor effects.
• To emphasize the need for integrated approaches combining immunotherapy and anti-infective strategies.

Main Methods:

• Review of current literature on multiple myeloma immunotherapies.
• Analysis of the role of prophylactic and therapeutic antibiotics in MM.
• Discussion of the interplay between infection, immunity, and tumor biology in MM.

Main Results:

• Immunotherapies such as CAR T-cells and checkpoint inhibitors are transforming MM treatment.
• Antibiotics possess both anti-infective and potential anti-tumor properties by reducing inflammation.
• Combined therapies offer a promising strategy to overcome MM-associated immune dysfunction.

Conclusions:

• Optimizing combined immunotherapies and anti-infective strategies is crucial for improving MM prognosis.
• Further research into the complex interplay of infection, immunity, and MM is warranted.
• Integrated treatment approaches hold the key to better managing this hematological malignancy.